Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.

Item
http://www.wikidata.org/entity/Q51343168
Visceral adiposity index: an indicator of adipose tissue dysfunction.Hyperprolactinaemia - a problem in patients from the reproductive period to the menopause.The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergolineAssociation between serum prolactin levels and insulin resistance in non-diabetic menVisceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma.Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency.
P2860

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.

Item
http://www.wikidata.org/entity/Q51343168
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@en
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@nl
type
label
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@en
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@nl
prefLabel
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@en
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698